Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...

Scientists discover that the CD74 protein could predict the effectiveness of immunotherapy, advancing colon cancer treatment.

With minimal blood loss and scarring, and faster recovery period, robotic surgeries are becoming game changers in the ...

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...